4-[(3S,5R,8R,9S,10S,12R,13S,14S)-3-[(2S,4S,5R,6R)-5-[(2S,4S,5R,6R)-5-[(2S,4S,5R,6R)-4,5-dihydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-5H-furan-2-one
|
Absorption Bioavailability 100% (IV), 90% to 100% (capsules), 70% to 85% (elixir), 60% to 80% (tablets). T max is 1 to 3 h (oral). Food slows the rate of absorption after oral administration.
Distribution 6 to 8 h tissue distribution phase. Large apparent Vd. Crosses blood-brain barrier and placenta. Excreted in breast milk. Approximately 25% protein bound.
Metabolism Approximately 16% metabolized; metabolites formed by hydrolysis, oxidation, and conjugation.
Elimination Elimination follows first-order kinetics. 50% to 70% excreted unchanged in the urine (after IV administration). t ½ is 1.5 to 2 days.
Onset 0.5 to 2 h (oral), 5 to 30 min (IV).
Peak 2 to 6 h (oral), 1 to 4 h (IV).
Special Populations Renal Function Impairment Cl correlates with Ccr. Dosage adjustment recommended.
|